Anonymous (2026). Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries.. European heart journal.
Anonymous. Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries.. European heart journal. 2026; PMID: 42199067
Anonymous. Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries.[J]. European heart journal. 2026.
@article{paper2026,
author = {Anonymous},
title = {Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries.},
journal = {European heart journal},
year = {2026},
note = {PMID: 42199067},
}
TY - JOUR AU - Anonymous TI - Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. T2 - European heart journal PY - 2026 AN - PMID:42199067 ER -
Chimeric antigen receptor T-cell (CAR-T) therapies are cellular immunotherapies that improve survival in patients with relapsed haematologic malignancies. However, their association with major adverse cardiovascular events (MACE) has received limited study, particularly in older adults. This study investigated the incidence of MACE, associated risk factors, and their impact on survival among older patients undergoing CAR-T in the USA.